Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!
What Are the Projected Market Size and Growth Rates for the Acute Myocardial Infarction Market From 2025 To 2029?
In recent times, the market size for acute myocardial infarction has seen robust growth. The market is projected to escalate from $1.47 billion in 2024 to $1.56 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. Factors such as an increase in heart diseases related to smoking, a rising incidence of hypertension, enhanced emergency medical services, heightened consciousness of risk factors related to heart disease, and the preliminary application of aspirin in cardiovascular care have contributed to the growth during the historic period.
In the coming years, a robust growth is forecasted in the market size for acute myocardial infarction. It’s projected to rise to $1.97 billion by 2029, with a compound annual growth rate (CAGR) of 6.0%. This anticipated growth within the forecast period can be linked to the increasing demand for less invasive heart procedures, enhanced investments in heart repair regenerative medicine, a surge in obesity and diabetes, and a heightened concentration on customised heart disease treatments. Notable trends for the forecast period encompass AI-powered early detection systems, wearable ECG monitoring devices, drug delivery using nanotechnology, 3D bioprinting of heart tissues, and state-of-the-art robotic-assisted heart surgeries.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23291&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Acute Myocardial Infarction Market?
The acute myocardial infarction market is likely to grow due to the escalating cases of hypertension. Hypertension, a medical condition marked by consistently high blood pressure, enhances the possibilities of heart diseases, strokes, and other health issues. The rise in hypertension cases can be attributed to the proliferation of sedentary lifestyles, which includes desk jobs, extended screen viewing, and lack of physical activity. The role of hypertension in acute myocardial infarction is through arterial damage, plaque accumulation, and an escalated risk of blood clots that could obstruct coronary arteries. For example, in October 2024, a report by the Australian Bureau of Statistics, a government agency based in Australia, revealed that the rate of hypertension spiked to 11.6% (3.0 million people) in 2022. Hence, the ascending cases of hypertension are fueling the expansion of the acute myocardial infarction market.
Which Key Market Segments Comprise the Acute Myocardial Infarction Market and Drive Its Revenue Growth?
The acute myocardial infarction market covered in this report is segmented –
1) By Type: ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI)
2) By Treatment Type: Thrombolytic Therapy, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG), Medications
3) By Diagnosis Method: Electrocardiogram, Cardiac Biomarkers, Echocardiography, Coronary Angiography, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan
4) By Route Of Administration: Oral Route, Intravenous (IV) Route, Subcutaneous Route, Transdermal Route, Sublingual Route
5) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Specialty Cardiac Centers, Research Institutes
Subsegments:
1) ST-Elevation Myocardial Infarction (STEMI): Anterior ST-Elevation Myocardial Infarction (STEMI), Inferior ST-Elevation Myocardial Infarction (STEMI), Posterior ST-Elevation Myocardial Infarction (STEMI), Lateral ST-Elevation Myocardial Infarction (STEMI), Right Ventricular ST-Elevation Myocardial Infarction (STEMI), Extensive (Large) ST-Elevation Myocardial Infarction (STEMI)
2) Non-ST-Elevation Myocardial Infarction (NSTEMI): Subendocardial Non-ST-Elevation Myocardial Infarction (NSTEMI), Partial Thickness Non-ST-Elevation Myocardial Infarction (NSTEMI), Multi-Vessel Non-ST-Elevation Myocardial Infarction (NSTEMI), Silent Non-ST-Elevation Myocardial Infarction (NSTEMI), Recurrent Non-ST-Elevation Myocardial Infarction (NSTEMI)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23291&type=smp
Which Areas Are Leading Regions in the Acute Myocardial Infarction Market Expansion Across the Globe?
North America was the largest region in the acute myocardial infarction market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in the Acute Myocardial Infarction Market Over the Coming Years?
Key players in the acute myocardial infarction market are prioritizing gaining regulatory approvals as a strategy to increase their product range, boost treatment effectiveness, and solidify their standing in the market. Regulatory approvals denote formal permissions from health authorities like the FDA and EMA, validating that drugs and medical devices comply with safety, effectiveness, and quality benchmarks prior to market introduction. For instance, Sungen Biomedical, a Chinese biopharmaceutical firm, achieved an FDA Fast Track Designation for its monoclonal antibody drug, SGC001, the first-ever developed worldwide to manage acute myocardial infarction (AMI) emergencies, in March 2025. This designation validates the potential of SGC001 to lower cardiomyocyte apoptosis and enhance blood circulation in ischemic regions. Given the encouraging preclinical outcomes showing recovery benefits and mortality reduction, the Fast Track status allows for accelerated FDA interactions, speeding up the approval procedure and guaranteeing faster patient access to this groundbreaking AMI treatment.
View the full report here:
https://www.thebusinessresearchcompany.com/report/acute-myocardial-infarction-global-market-report
How Is the Acute Myocardial Infarction Market Conceptually Defined?
Acute myocardial infarction (MI), commonly referred to as a heart attack, is characterized by the death of heart muscle tissue due to a sudden decrease or cessation of blood flow in one or more coronary arteries. This condition leads to myocardial necrosis, primarily caused by the rupture of atherosclerotic plaques, which results in acute obstruction of blood flow.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23291
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model